Ovarian Cancer Drugs Market
Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, and PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2024-2031)
Ovarian cancer drugs market is anticipated to grow at a significant CAGR of 15.4% during the forecast period (2024-2031). The rising incidence of ovarian cancer globally is driving the growth of the global ovarian cancer drugs market. The advancements in drug development, personalized medicine, improved diagnostic techniques, awareness, government support, and technological innovations are key factors driving market growth and improving treatment outcomes.
Market Dynamics
Rising Incidence and Prevalence
The global rise in ovarian cancer cases, particularly in elderly individuals, is driving demand for effective treatments and driving market growth. According to, the American Cancer Society, in January 2024, estimates for ovarian cancer in the US 2024, that approximately 19,680 individuals will receive a new diagnosis of ovarian cancer, and about 12,740 ovarian cancers predominantly affect elderly individuals, with half diagnosed at 63 years old, and is more frequently diagnosed in Whites than in Blacks.
Growing Awareness and Demand for Personalized Treatments
The growing awareness of personalized medicine benefits is driving demand for genomic testing and tailored therapies, contributing to the growth of the ovarian cancer drugs market. For instance, in June 2023, USask launched a clinical trial to improve ovarian cancer treatment, aiming to enhance quality of life and reduce costs. The trial combined multiple tumor test methods, providing patients with personalized genomic information about their tumors, enabling informed care choices and drug benefit estimates.
Market Segmentation
- Based on the drug class, the market is segmented into PARP Inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors.
- Based on the therapy, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others (hormonal therapy).
Chemotherapy is Projected to Hold the Largest Segment
The combination treatments, such as angiogenesis inhibitors, PD-L1 inhibitors, PARP inhibitors, and chemotherapy, have enhanced efficacy in clinical trials, changing therapeutic paradigms and driving market growth. For instance, in April 2023, a DUO-O Phase III trial showed that a combination of Lynparza and Imfinzi improved progression-free survival in patients with advanced ovarian cancer without tumor BRCA mutations. The treatment, which included Imfinzi, chemotherapy, and bevacizumab, showed a significant improvement in PFS compared to the control arm.
Regional Outlook
The global ovarian cancer drugs market is further segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Global Ovarian Cancer Drugs Market Growth by Region 2024-2031
North America Holds Major Market Share
Rising healthcare expenditures in the US boost funding for cancer research and drug development, promoting the development of new therapies and advancements in existing treatments for ovarian cancer. According to the American Medical Association, in July 2024, health spending in the US rose by 4.1% in 2022, reaching a total of $4.5 trillion or $13,493 per capita. This growth rate aligns with pre-pandemic levels, such as the 4.1% increase seen in 2019. While pandemic-related government spending led to significant rises in National Health Expenditures (NHE), these costs decreased in 2021, and the use of medical goods and services returned to pre-pandemic levels by 2022. ?
Market Players Outlook
*Note: Major Players Sorted in No Particular Order.
The major companies serving the global ovarian cancer drugs market include AstraZeneca, F. Hoffmann-La Roche Ltd, Merck Group, Eli Lilly and Co., and Pfizer Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.
Recent Developments
- In July 2024, Anixa Biosciences received FDA approval for a second dose of its ovarian cancer CAR-T therapy, following positive results in a patient from the lowest dose cohort. The Phase I clinical trial at Moffitt Cancer Center is treating recurrent ovarian cancer patients who have failed standard therapies.
- In October 2023, Daiichi Sankyo and Merck signed a global development and commercialization agreement for three of Daiichi Sankyo's DXd antibody-drug conjugate candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). The candidates are in clinical development for multiple solid tumor treatments. Patritumab deruxtecan, granted Breakthrough Therapy.
The Report Covers
- Market value data analysis of 2023 and forecast to 2031.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global ovarian cancer drugs market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Industry Trends
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. AstraZeneca plc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. F. Hoffmann-La Roche Ltd
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Merck Group
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Key Strategy Analysis
4. Market Segmentation
4.1. Global Ovarian Cancer Drugs Market by Drug Class
4.1.1. PARP Inhibitors
4.1.2. Angiogenesis Inhibitors
4.1.3. PD-L1 Inhibitors
4.2. Global Ovarian Cancer Drugs Market by Therapy
4.2.1. Chemotherapy
4.2.2. Targeted Therapy
4.2.3. Immunotherapy
4.2.4. Others (Hormonal Therapy)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
5.4.1. Latin America
5.4.2. Middle East and Africa
6. Company Profiles
6.1. AbbVie Ltd.
6.2. Amgen Inc.
6.3. BioMarin
6.4. Boehringer Ingelheim International GmbH
6.5. Bristol Myers Squibb
6.6. Eisai Co., Ltd.
6.7. Eli Lilly and Co.
6.8. Exelixis, Inc.
6.9. Genentech, Inc.
6.10. ImmunoGen, Inc.
6.11. Johnson & Johnson Services, Inc.
6.12. Mersana Therapeutics, Inc.
6.13. Novartis Pharma AG
6.14. Pfizer Inc.
6.15. Sanofi-aventis Australia Pty Ltd.
6.16. Takeda Pharmaceutical Co. Ltd.
1. Global Ovarian Cancer Drugs Market Research And Analysis By Drug Class, 2023-2031 ($ Million)
2. Global PARP Inhibitors Ovarian Cancer Drugs Market Research And Analysis By Region, 2023-2031 ($ Million)
3. Global Angiogenesis Inhibitors Ovarian Cancer Drugs Market Research And Analysis By Region, 2023-2031 ($ Million)
4. Global PD-L1 Inhibitors Ovarian Cancer Drugs Market Research And Analysis By Region, 2023-2031 ($ Million)
5. Global Ovarian Cancer Drugs Market Research And Analysis By Therapy, 2023-2031 ($ Million)
6. Global Ovarian Cancer Drugs In Chemotherapy Market Research And Analysis By Region, 2023-2031 ($ Million)
7. Global Ovarian Cancer Drugs In Targeted Therapy Market Research And Analysis By Region, 2023-2031 ($ Million)
8. Global Ovarian Cancer Drugs In Immunotherapy Market Research And Analysis By Region, 2023-2031 ($ Million)
9. Global Ovarian Cancer Drugs In Other Therapy Market Research And Analysis By Region, 2023-2031 ($ Million)
10. Global Ovarian Cancer Drugs Market Research And Analysis By Region, 2023-2031 ($ Million)
11. North American Ovarian Cancer Drugs Market Research And Analysis By Country, 2023-2031 ($ Million)
12. North American Ovarian Cancer Drugs Market Research And Analysis By Drug Class, 2023-2031 ($ Million)
13. North American Ovarian Cancer Drugs Market Research And Analysis By Therapy, 2023-2031 ($ Million)
14. European Ovarian Cancer Drugs Market Research And Analysis By Country, 2023-2031 ($ Million)
15. European Ovarian Cancer Drugs Market Research And Analysis By Drug Class, 2023-2031 ($ Million)
16. European Ovarian Cancer Drugs Market Research And Analysis By Therapy, 2023-2031 ($ Million)
17. Asia-Pacific Ovarian Cancer Drugs Market Research And Analysis By Country, 2023-2031 ($ Million)
18. Asia-Pacific Ovarian Cancer Drugs Market Research And Analysis By Drug Class, 2023-2031 ($ Million)
19. Asia-Pacific Ovarian Cancer Drugs Market Research And Analysis By Therapy, 2023-2031 ($ Million)
20. Rest Of The World Ovarian Cancer Drugs Market Research And Analysis By Region, 2023-2031 ($ Million)
21. Rest Of The World Ovarian Cancer Drugs Market Research And Analysis By Drug Class, 2023-2031 ($ Million)
22. Rest Of The World Ovarian Cancer Drugs Market Research And Analysis By Therapy, 2023-2031 ($ Million)
1. Global Ovarian Cancer Drugs Market Share By Drug Class, 2023 Vs 2031 (%)
2. Global PARP Inhibitors Ovarian Cancer Drugs Market Share By Region, 2023 Vs 2031 (%)
3. Global Angiogenesis Inhibitors Ovarian Cancer Drugs Market Share By Region, 2023 Vs 2031 (%)
4. Global PD-L1 Inhibitors Ovarian Cancer Drugs Market Share By Region, 2023 Vs 2031 (%)
5. Global Ovarian Cancer Drugs Market Share By Therapy, 2023 Vs 2031 (%)
6. Global Ovarian Cancer Drugs In Chemotherapy Market Share By Region, 2023 Vs 2031 (%)
7. Global Ovarian Cancer Drugs In Targeted Therapy Market Share By Region, 2023 Vs 2031 (%)
8. Global Ovarian Cancer Drugs In Immunotherapy Market Share By Region, 2023 Vs 2031 (%)
9. Global Ovarian Cancer Drugs In Other Therapy Market Share By Region, 2023 Vs 2031 (%)
10. Global Ovarian Cancer Drugs Market Share By Region, 2023 Vs 2031 (%)
11. US Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
12. Canada Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
13. UK Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
14. France Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
15. Germany Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
16. Italy Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
17. Spain Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
18. Rest Of Europe Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
19. India Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
20. China Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
21. Japan Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
22. South Korea Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
23. Rest Of Asia-Pacific Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
24. Latin America Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
25. Middle East And Africa Ovarian Cancer Drugs Market Size, 2023-2031 ($ Million)
